Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2 TMB-H 1 Recurrence 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Liver Neoplasms 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Biliary Tract Neoplasms 1

Interventions

Bevacizumab 23 Sorafenib 20 Doxorubicin 14 Gemcitabine 11 durvalumab 10 Oxaliplatin 10 Fluorouracil 10 Cisplatin 10 Capecitabine 9 Nivolumab 8 pembrolizumab 6 Sunitinib 6 tremelimumab 5 atezolizumab 5 Radiofrequency Ablation 5 Neoadjuvant Therapy 5 Leucovorin 5 lenvatinib 4 aldesleukin 4 Thalidomide 4 Radiotherapy 4 Radiosurgery 4 Everolimus 4 Erlotinib Hydrochloride 4 Drug Therapy 4 Carboplatin 4 toripalimab 3 regorafenib 3 camrelizumab 3 apatinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liver Neoplasms × IMC-001 × Clear all

NCT04196465 2026-05-22

NeoChance

Asan Medical Center

Phase 2 Active not recruiting

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡